• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
ASCO 2025: Changes in colorectal cancer screening and detection following USPSTF expanded recommendations

ASCO 2025: Changes in colorectal cancer screening and detection following USPSTF expanded recommendations

by Truveta Research | May 30, 2025 | Research, Research Insights

Authors: Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Jennifer Liang, MD ⊕Truveta, Inc, Bellevue, WA, Keenan Robbins, MBBS ⊕Washington University...
Evaluating recent trends in early measles vaccinations in Texas

Evaluating recent trends in early measles vaccinations in Texas

by Truveta Research | May 16, 2025 | Research, Research Insights

Among children in Texas receiving a first measles vaccine prior to two years of life: In March and April 2025, 20.1% of all first measles vaccines were administered to children early (6-11 months). This is 11.5-fold higher than in 2019, when there were international...
Cancer innovation needs better data—not just better drugs

Cancer innovation needs better data—not just better drugs

by Truveta staff | May 15, 2025 | Data

Cancer is one of the most heavily funded areas of medical research. And yet, with thousands of therapies in development and billions of dollars spent each year, many foundational questions persist: Why do patients stop treatment? How do outcomes vary across...
ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Side effects were the most common...
ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention 

ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention 

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Moderate adherence was observed for...
« Older Entries
Next Entries »

Share this


Recent posts

  • Real-world survival outcomes for CRT and CCM therapies align with landmark trials
  • Understanding the potential impact of the upcoming ACIP vote on thimerosal-containing influenza vaccines
  • Biosimilar use is on the rise – but 1 in 8 patients return to Humira

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice